2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
<p><strong>Objective</strong></p> <p>To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NP...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2018
|
| _version_ | 1826288078733443072 |
|---|---|
| author | Singh, J Guyatt, G Ogdie, A Gladman, D Deal, C Deodhar, A Dubreuil, M Dunham, J Husni, M Kenny, S Kwan-Morley, J Lin, J Marchetta, P Mease, P Merola, J Miner, J Ritchlin, C Siaton, B Smith, B Van Voorhees, A Jonsson, A Shah, A Sullivan, N Turgunbaev, M Coates, L Gottlieb, A Magrey, M Nowell, W Orbai, A Reddy, S Scher, J Siegel, E Siegel, M Walsh, J Turner, A Reston, J |
| author_facet | Singh, J Guyatt, G Ogdie, A Gladman, D Deal, C Deodhar, A Dubreuil, M Dunham, J Husni, M Kenny, S Kwan-Morley, J Lin, J Marchetta, P Mease, P Merola, J Miner, J Ritchlin, C Siaton, B Smith, B Van Voorhees, A Jonsson, A Shah, A Sullivan, N Turgunbaev, M Coates, L Gottlieb, A Magrey, M Nowell, W Orbai, A Reddy, S Scher, J Siegel, E Siegel, M Walsh, J Turner, A Reston, J |
| author_sort | Singh, J |
| collection | OXFORD |
| description | <p><strong>Objective</strong></p>
<p>To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).
<p><strong>Methods</strong></p>
<p>We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations.</p>
<p><strong>Results</strong></p>
<p>The guideline covers the management of active PsA in patients who are treatment‐naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin‐12/23 inhibitors (IL‐12/23i), IL‐17 inhibitors, CTLA4‐Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat‐to‐target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment.</p>
<p><strong>Conclusion</strong></p>
<p>The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.</p> |
| first_indexed | 2024-03-07T02:08:18Z |
| format | Journal article |
| id | oxford-uuid:9fbd9198-af83-4c96-bb5e-d15257241d1a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:08:18Z |
| publishDate | 2018 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:9fbd9198-af83-4c96-bb5e-d15257241d1a2022-03-27T02:00:15Z2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9fbd9198-af83-4c96-bb5e-d15257241d1aEnglishSymplectic Elements at OxfordWiley2018Singh, JGuyatt, GOgdie, AGladman, DDeal, CDeodhar, ADubreuil, MDunham, JHusni, MKenny, SKwan-Morley, JLin, JMarchetta, PMease, PMerola, JMiner, JRitchlin, CSiaton, BSmith, BVan Voorhees, AJonsson, AShah, ASullivan, NTurgunbaev, MCoates, LGottlieb, AMagrey, MNowell, WOrbai, AReddy, SScher, JSiegel, ESiegel, MWalsh, JTurner, AReston, J<p><strong>Objective</strong></p> <p>To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). <p><strong>Methods</strong></p> <p>We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations.</p> <p><strong>Results</strong></p> <p>The guideline covers the management of active PsA in patients who are treatment‐naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin‐12/23 inhibitors (IL‐12/23i), IL‐17 inhibitors, CTLA4‐Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat‐to‐target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment.</p> <p><strong>Conclusion</strong></p> <p>The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.</p> |
| spellingShingle | Singh, J Guyatt, G Ogdie, A Gladman, D Deal, C Deodhar, A Dubreuil, M Dunham, J Husni, M Kenny, S Kwan-Morley, J Lin, J Marchetta, P Mease, P Merola, J Miner, J Ritchlin, C Siaton, B Smith, B Van Voorhees, A Jonsson, A Shah, A Sullivan, N Turgunbaev, M Coates, L Gottlieb, A Magrey, M Nowell, W Orbai, A Reddy, S Scher, J Siegel, E Siegel, M Walsh, J Turner, A Reston, J 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title | 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title_full | 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title_fullStr | 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title_full_unstemmed | 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title_short | 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis |
| title_sort | 2018 american college of rheumatology national psoriasis foundation guideline for the treatment of psoriatic arthritis |
| work_keys_str_mv | AT singhj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT guyattg 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT ogdiea 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT gladmand 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT dealc 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT deodhara 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT dubreuilm 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT dunhamj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT husnim 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT kennys 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT kwanmorleyj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT linj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT marchettap 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT measep 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT merolaj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT minerj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT ritchlinc 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT siatonb 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT smithb 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT vanvoorheesa 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT jonssona 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT shaha 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT sullivann 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT turgunbaevm 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT coatesl 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT gottlieba 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT magreym 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT nowellw 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT orbaia 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT reddys 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT scherj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT siegele 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT siegelm 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT walshj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT turnera 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis AT restonj 2018americancollegeofrheumatologynationalpsoriasisfoundationguidelineforthetreatmentofpsoriaticarthritis |